Načítá se...
Sorafenib for the treatment of hepatocellular carcinoma
The multikinase inhibitor sorafenib, which inhibits targets related to tumor cell proliferation and angiogenesis, was the first systemic agent to demonstrate a significant improvement in the overall survival for patients with advanced hepatocellular carcinoma (HCC) in two large randomized controlled...
Uloženo v:
| Vydáno v: | Hepat Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Future Medicine Ltd
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095169/ https://ncbi.nlm.nih.gov/pubmed/30190954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep.13.20 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|